Hooked on Drug Money: Will Congress Take a Stand on Medicare?
By Dean Baker
t r u t h o u t | Columnist
Wednesday 10 January 2007
It's payback time, as the lobbyists say in Washington. One of the key planks in the Democrats' election platform was changing the Medicare drug benefit by allowing Medicare to negotiate lower prices with the pharmaceutical industry. While this may not have been as important to their victory as the war, voters were outraged by the Medicare drug bill approved by Republican Congress. The benefit was designed to enrich the pharmaceutical and insurance industries at the expense of taxpayers and beneficiaries.
Now the Democrats are in a position to make good on their promise to reform the bill, and the pharmaceutical industry is going all out to protect its future profits. The basic story here is very simple. The prices paid by the insurers participating in the Medicare program are far higher than the prices paid by the Veterans Administration or governments that negotiate directly with the drug companies.
If Medicare negotiated similar discounts with the industry, it could save taxpayers and beneficiaries between $300 and $400 billion dollars over the next decade. This comes to between $2,500 and $3,500 per household. In technical terms, this is real money.
In order to protect its profits and the big bucks earned by the CEOs, the industry is pulling out all the stops to make its case. This means making every claim imaginable, some of which are even contradictory.
Claim #1 is that the government cannot get lower prices than the private insurers. This could be true if the people running the Medicare program were uniquely incompetent. We have the data. The Veterans Administration pays prices that average 40 percent less than the insurers participating in the Medicare program. The same is true of the Canadian government, the Australian government, and all the other governments of wealthy countries that run health care programs. If we really have such incompetent people running Medicare, then we need to replace them with qualified managers, but that is not an argument against reforming the program.
It is important to remember that drugs are cheap. Wal-Mart is selling prescriptions of most generic drugs at $4 a piece. The only difference between the drugs that Wal-Mart sells for $4 and the ones that cost hundreds of dollars is that the latter enjoy government-created patent monopolies. It is only these patent monopolies that make drugs expensive; in nearly all cases they are cheap to produce. In principle, nearly all drugs could be profitably sold at $4 per prescription.
Claim #2 is that if Medicare negotiated prices, beneficiaries would only be able to get the drugs chosen by the government. This is wrong as well. The Veterans Administration has a formulary with preferred drugs available at lower prices. If patients have a need for drugs not on the formulary, they can still get them, they just pay a higher price - a price comparable to what the private insurers pay now. ......(more)
The rest of the article is at:
http://www.truthout.org/docs_2006/011007A.shtml